pharma news today obesity glp-1 New Pill Foundayo (Orforglipron) Gets FDA Approval for Some US employers to drop

Nutricin Hospitalaria

Importantly, these appetite changes were associated with a 16% lower energy intake at the subsequent ad libitum lunch with liraglutidemore than 500 kJ compared with placebo

1 x gommes la vitamine C

Our Research Lead examined anonymized platform data from: 5,864 US adults using tirzepatide (Mounjaro or Zepbound) 4,456 US adults using semaglutide (Ozempic or Wegovy) Inclusion criteria: Active GLP-1 therapy with weekly injections Minimum 12-week tracking duration Adherence threshold: 1 injection log and 1 weight entry per week No weight entries outside physiological bounds (30300 kg) or with weekly changes exceeding 5% Primary outcome: Percentage body weight change from baseline, calculated as [(current weight baseline weight) / baseline weight] 100 , where negative values indicate weight loss Data collection period: Data were collected from all available platform records through January 2026, representing naturalistic use patterns without researcher intervention

EC 50 values extrapolated from dose-response curves for the top 7 double hits are shown in Table 1